Glioblastoma multiforme (GBM) is a highly malignant astrocytic tumor composed of complex and differentiated neoplastic astrocytes that are a subtype of the central nervous system (CNS). The glioblastoma multiforme treatment market is estimated to expand at a steady CAGR of 11.4% till 2022 and reach a value of US$0.34 billion.
Glioblastoma multiforme is an aggressive tumor and is the most lethal brain tumor among adults. Glioblastoma multiforme treatment is done by surgical resection, which is followed by radiotherapy and chemotherapy, but these do not increase overall survival rate in patients, since GBM is an invasive disease. Glioma stem cells resist conventional treatments, hence there is an urgent need for alternative treatment therapies for glioblastoma multiforme.
Technological Advancement of Treatment Modalities to Shape GBM Treatment Market
Recently, there has been significant progress in molecular biology and in gene technology, both of which have contributed to new treatment opportunities for patients diagnosed with glioblastoma multiforme. There are many challenges and impediments to GBM treatment. Patients diagnosed with GBM have a poor survival rate, as the available treatments are often ineffective. In the U.S., among the approximately 22,000 adults who were diagnosed with primary malignant tumors of the brain and spinal cord, gliomas were recorded as the type with the highest incidence.
The glioblastoma multiforme treatment market is categorized by type of therapies and geographical regions. The three drugs that have a major market share for glioblastoma multiforme treatment are bevacozumab, temozolomide, and carmustine. Carmustine has the brand name of Gliadel from Arbor Pharmaceuticals, LLC, and is a surgical implant. Bevacozumab, known by its brand name Avastin, is a product of Genetech/Roche and is used in intravenous therapy. The third drug for GBM treatment is temozolomide and is known by the brand names Temodal/Temodar/Temcad. It is used in oral or intravenous chemotherapy.
The main market drivers for glioblastoma multiforme treatment are development in drug delivery and diagnostic techniques, and growing awareness about the various types of brain tumors. Due to the effectiveness of temozolomide, when combined with surgery, it had the largest market share in 2013. Bevacozumab is expected to exceed temozolomide by 2016 as it is the first drug approved for treatment of GBM and has monoclonal antibody properties.
North America Leads Market due to Governmental and Non-governmental Initiatives
In the geographical market segments for glioblastoma multiforme treatment (GBM), North America leads the market due to intensification in governmental and non-governmental support for glioblastoma multiforme treatment (GBM). There has been an upsurge in the activities of associations such as National Brain Tumor Society, Brain Tumor Foundation of Canada, and American Brain Tumor Association, which are involved in raising awareness about GBM. Manufacturers of the drugs for glioblastoma multiforme treatment are also based in the region and hence contribute to the expansion of the glioblastoma multiforme treatment market in North America. The Asia Pacific segment of the glioblastoma multiforme treatment market is a rapidly growing market for GBM treatment, due to updation of healthcare infrastructure and rising awareness of GBM.
The major players in the glioblastoma multiforme treatment (GBM) market are Arbor Pharmaceuticals, LLC., Merck & Co., Inc., and F. Hoffmann-Le Roche AG.
Enquiry For Sample Report Visit:- http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4807
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
Albany NY – 12207